Slide 1: AUA Investor Call
AUA Investor Call Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer May 15, 2026 NASDAQ: CADL
Slide 2: Forward-looking statements
Forward-looking statements This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Presentation, including express or implied statements regarding our
Slide 3: Conference Call Agenda
Conference Call Agenda 1. Introduction & Welcome Dr. Paul Peter Tak, CEO | 5 mins 2. Data Presentation Dr. Garrett Nichols, CMO | 10 mins 3. Panel Discussion Moderated by Dr. Paul Peter Tak, CEO | 20 mins Panelists: Dr. Steven Finkelstein, Dr. Daniel George, Dr. Neal Shore 4. Live Q&A Financial anal
Slide 4: Extended follow-up shows accumulating benefit for patients treated with aglatimagene besadenovec
Extended follow-up shows accumulating benefit for patients treated with aglatimagene besadenovec (CAN-2409) + prodrug in combination with standard-of-care external beam radiation (EBRT) in men with localized prostate cancer: update from a randomized placebo-controlled phase 3 clinical trial Mark Gar
Slide 5: Disclosures
Disclosures Dr. Garzotto has served as a clinical trial investigator for Astellas Pharma, Candel Therapeutics, Merck & Co., and Pfizer. He also served as a consultant to Candel Therapeutics 5
Slide 6: Unmet need in localized prostate cancer
Unmet need in localized prostate cancer Global concern: approximately 1.4 million new cases of prostate cancer in 20201 Incidence in US2 INTERMEDIATE HIGH LOW RISK RISK RISK 65K 109K 43K Patients Currently Receiving Radiotherapy ~65K (~43%) Ultimate goal of curative treatment is prevention of cancer
Slide 7: Aglatimagene besadenovec + prodrug: Overview of mechanism of action
Aglatimagene besadenovec + prodrug: Overview of mechanism of action 1 Intratumoral gene 2 Prodrug activation 3 Radiotherapy synergy 4 Anti-tumor 5 Local and systemic delivery immune priming disease control Aglatimagene is a replication- HSV-TK converts prodrug Radiation synergizes with Tumor cell de
Slide 8: Aglatimagene besadenovec injection procedure
Aglatimagene besadenovec injection procedure PROCEDURE STEPS Patient Position 1 • Position: knee-chest (lateral) or lithotomy, as in standard TRUS- guided biopsy • Approach: transrectal or transperineal — both acceptable • Setting: in-office or ASC; local block or IV sedation typically sufficient II
Slide 9: Injection and radiation sequencing schedule
Injection and radiation sequencing schedule t -14d t=0d t +14d 14 days prior to radiotherapy Start of RT 14 days after prior injection 14-day course 14-day course 14-day course valacyclovir valacyclovir valacyclovir INJECTION SCHEDULE INJECTION #1 (t−14d) INJECTION #2 (t=0) INJECTION #3 (t+14d) RT M
Slide 10: Phase 3 clinical trial of aglatimagene in newly diagnosed, intermediate- to high-risk, localized prostate cancer
Phase 3 clinical trial of aglatimagene in patients with newly diagnosed, intermediate- to high-risk, localized prostate cancer NCT01436968 Aglatimagene + valacyclovir Primary endpoints • Disease-free survival (time to (3 injection courses + radiotherapy cancer recurrence or death due n=745 with or w
Slide 11: Disease-free survival in localized prostate cancer treated with curative intent
Disease-free survival in localized prostate cancer treated with curative intent DFS: time from randomization to prostate cancer recurrence (biopsy, clinical, or radiographic evidence), metastasis, or death from any cause Prostate cancer-specific DFS: time from randomization to prostate cancer recurr
Slide 12: Demographic and baseline characteristics of randomized patients
Demographic and baseline characteristics of randomized patients Aglatimagene + prodrug Placebo + prodrug Total ITT population (N=745) (N=496) (N=249) (N=745) Median age (yrs) 69 68 69 Race, n (%) White/Caucasian 385 (77.6) 206 (82.7) 591 (79.3) Black/African American 93 (18.8) 28 (11.2) 121 (16.2) A
Slide 13: Aglatimagene significantly improved prostate cancer-specific disease-free survival after extended follow-up
Aglatimagene significantly improved prostate cancer-specific disease-free survival after extended follow-up (ITT, N = 745) Aglatimagene + SoC resulted in 39% improvement in prostate cancer-specific DFS compared to PBO + SoC Only 2 deaths due to prostate cancer (1 each arm) after median follow- HR=0.
Slide 14: Longer time to salvage anticancer therapy and biochemical failure observed in aglatimagene arm
Longer time to salvage anticancer therapy and biochemical failure observed in aglatimagene arm (ITT, N=745) Time to new anticancer therapy Time to biochemical failure (nadir+2) HR=0.72; 95% CI 0.39 – 1.31 HR=0.72; 95% CI 0.40 – 1.31 DATA CUTOFF: MAR 15, 2026 Mark Garzotto, MD | AUA 2026, Washington
Slide 15: Lower incidence of and increased time to metastasis observed in aglatimagene arm
Lower incidence of and increased time to metastasis observed in aglatimagene arm (ITT, N = 745) Time to metastasis Aglatimagene + SoC cohort experienced a lower rate of metastases Agla 8/496 (1.6%), PBO 7/249 (2.8%) HR=0.58; 95% CI 0.21 – 1.59 DATA CUTOFF: MAR 15, 2026 Mark Garzotto, MD | AUA 2026,
Slide 16: Improved prostate cancer-specific DFS in intermediate-risk prostate cancer
Aglatimagene significantly improved prostate cancer-specific disease- free survival in intermediate-risk prostate cancer (n = 635) Aglatimagene + SoC resulted in 41% improvement in prostate cancer-specific DFS compared to PBO + SoC HR=0.59; 95% CI 0.41 - 0.84 p=0.0034 DATA CUTOFF: MAR 15, 2026 Mark
Slide 17: Longer time to salvage therapy and biochemical failure in intermediate-risk
Longer time to salvage anticancer therapy and biochemical failure observed in aglatimagene arm in intermediate-risk prostate cancer (n = 635) Time to new anticancer therapy Time to biochemical failure (nadir+2) HR=0.51; 95% CI 0.24 - 1.1 HR=0.48; 95% CI 0.22 – 1.03 DATA CUTOFF: MAR 15, 2026 Mark Gar
Slide 18: Lower incidence of and increased time to metastases in intermediate-risk
Lower incidence of and increased time to metastases observed in aglatimagene arm in intermediate-risk prostate cancer (n = 635) Time to metastasis Aglatimagene + SoC cohort experienced lower rate of metastatic disease Agla 1/422 (0.24%), PBO 5/213 (2.35%) HR=0.1; 95% CI 0.01 – 0.85 DATA CUTOFF: MAR
Slide 19: Aglatimagene in combination with SoC radiation +/- ADT was generally well tolerated
Aglatimagene in combination with SoC radiation +/- ADT was generally well tolerated 0 5.8% vs 7.3% 5.4% vs 6.0% Grade ≥4 TRAEs SAE incidence Discontinuation due to AEs No serious treatment-related events Aglatimagene + SOC vs placebo + SOC Aglatimagene + SOC vs placebo + SOC Treatment related AEs >5
Slide 20: Accumulating clinical benefit for patients treated with aglatimagene in combination with EBRT
Accumulating clinical benefit for patients treated with aglatimagene in combination with EBRT after extended follow-up Previously presented primary endpoint demonstrated statistically significant improvement in DFS as well as increased pathological complete response in 2-year biopsies1, known to be
Slide 21: Panel Commentary
Panel Commentary May 15, 2026 NASDAQ: CADL
Slide 22: Q & A Financial Analysts
Q&A Financial Analysts May 15, 2026 NASDAQ: CADL
Slide 23: Thank You
Thank You May 15, 2026 NASDAQ: CADL